Clinical Trial

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study evaluate the additional effect of adding chemotherapy prior to resection of a pancreatic head malignancy. The patients will be randomized into two groups; surgery first (control group) and neoadjuvant chemotherapy (intervention). Primary endpoint is overall survival after resection
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2016-09-28; most recent amendment 2024-11-18.
Status change: Recruiting → Active, Not Recruiting 2021-06-25
Trial Details
NCT Number NCT02919787
Lead Sponsor Oslo University Hospital
Collaborators: St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, Sahlgrenska University Hospital, Karolinska University Hospital, University Hospital, Linkoeping, Lund University Hospital, Odense University Hospital, Helsinki University Hospital, Finland, Norrlands University Hospital, Helse Stavanger HF
Conditions Pancreatic Cancer
Enrollment 140 participants
Start Date 2016-09
Primary Completion 2022-12-22 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-20